Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) experienced a sharp increase after a significant regulatory victory in the UK. SNOA stock was up 63.94% at
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares were rising 11.90% to $3.95 as of this morning’s last pre-market check. SNOA has made a number of encouraging
The value Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares are increasing significantly today, indicating that the market has responded favorably to the company’s switch to a
Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under
Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a multinational healthcare giant, has released financial results for its second fiscal quarter and six months ended September 30, 2020,
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.